Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors
Introduction: Only a few reports have determined whether recently advanced anticancer drugs, particularly next-generation tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), prolong the survival of patients with NSCLC in the real world. Methods: To evaluate the association bet...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-06-01
|
| Series: | JTO Clinical and Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364323000632 |
| _version_ | 1797795237652856832 |
|---|---|
| author | Ryo Ariyasu, MD Sho Kakuto, MD Keiki Miyadera, MD Takahiro Akita, MD Ayu Kiritani, MD Ryosuke Tsugitomi, MD Yoshiaki Amino, MD Ken Uchibori, MD, PhD Satoru Kitazono, MD, PhD Noriko Yanagitani, MD, PhD Makoto Nishio, MD, PhD |
| author_facet | Ryo Ariyasu, MD Sho Kakuto, MD Keiki Miyadera, MD Takahiro Akita, MD Ayu Kiritani, MD Ryosuke Tsugitomi, MD Yoshiaki Amino, MD Ken Uchibori, MD, PhD Satoru Kitazono, MD, PhD Noriko Yanagitani, MD, PhD Makoto Nishio, MD, PhD |
| author_sort | Ryo Ariyasu, MD |
| collection | DOAJ |
| description | Introduction: Only a few reports have determined whether recently advanced anticancer drugs, particularly next-generation tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), prolong the survival of patients with NSCLC in the real world. Methods: To evaluate the association between recently advanced drugs and patient survival, survival data of 2078 patients with stage IV NSCLC from 1995 to 2022 were analyzed in the present study. The patients were classified into the following six groups in terms of the date of diagnosis: period A, 1995 to 1999; period B, 2000 to 2004; period C, 2005 to 2009; period D, 2010 to 2014; period E, 2015 to 2019; and period F, 2000 to 2022. They were further grouped in terms of EGFR mutation and ALK fusion. Results: The median overall survival (mOS) times were 8.9, 11.0, 13.6, 17.9, and 25.2 months in periods A to E, respectively, and the mOS time was not reached in period F. This time was significantly longer in period E than in period D (25.2 versus 17.9 mo, p < 0.005). Moreover, the mOS times of patients with EGFR mutation, those with ALK fusion, and those without both alterations were significantly longer in period E than in period D (46.0 versus 32.0 mo, p < 0.005; not reached versus 36.2 mo, p = 0.018; 14.6 versus 11.7 mo, p < 0.005). The history of treatment with next-generation TKIs and ICIs was found to be associated with overall survival. Conclusions: The survival of patients with NSCLC was improved from period D to period E, regardless of the presence of driver gene alteration. We found that next-generation TKIs and ICIs may be associated with improvements in overall survival. |
| first_indexed | 2024-03-13T03:14:54Z |
| format | Article |
| id | doaj.art-461d74d1b3d4494e8199e62cc0a7c7d3 |
| institution | Directory Open Access Journal |
| issn | 2666-3643 |
| language | English |
| last_indexed | 2024-03-13T03:14:54Z |
| publishDate | 2023-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JTO Clinical and Research Reports |
| spelling | doaj.art-461d74d1b3d4494e8199e62cc0a7c7d32023-06-26T04:14:52ZengElsevierJTO Clinical and Research Reports2666-36432023-06-0146100524Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint InhibitorsRyo Ariyasu, MD0Sho Kakuto, MD1Keiki Miyadera, MD2Takahiro Akita, MD3Ayu Kiritani, MD4Ryosuke Tsugitomi, MD5Yoshiaki Amino, MD6Ken Uchibori, MD, PhD7Satoru Kitazono, MD, PhD8Noriko Yanagitani, MD, PhD9Makoto Nishio, MD, PhD10Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JapanDepartment of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JapanDepartment of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JapanDepartment of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JapanDepartment of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JapanDepartment of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JapanDepartment of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JapanDepartment of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JapanDepartment of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JapanDepartment of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JapanCorresponding author. Address for correspondence: Makoto Nishio, MD, PhD, Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan.; Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JapanIntroduction: Only a few reports have determined whether recently advanced anticancer drugs, particularly next-generation tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), prolong the survival of patients with NSCLC in the real world. Methods: To evaluate the association between recently advanced drugs and patient survival, survival data of 2078 patients with stage IV NSCLC from 1995 to 2022 were analyzed in the present study. The patients were classified into the following six groups in terms of the date of diagnosis: period A, 1995 to 1999; period B, 2000 to 2004; period C, 2005 to 2009; period D, 2010 to 2014; period E, 2015 to 2019; and period F, 2000 to 2022. They were further grouped in terms of EGFR mutation and ALK fusion. Results: The median overall survival (mOS) times were 8.9, 11.0, 13.6, 17.9, and 25.2 months in periods A to E, respectively, and the mOS time was not reached in period F. This time was significantly longer in period E than in period D (25.2 versus 17.9 mo, p < 0.005). Moreover, the mOS times of patients with EGFR mutation, those with ALK fusion, and those without both alterations were significantly longer in period E than in period D (46.0 versus 32.0 mo, p < 0.005; not reached versus 36.2 mo, p = 0.018; 14.6 versus 11.7 mo, p < 0.005). The history of treatment with next-generation TKIs and ICIs was found to be associated with overall survival. Conclusions: The survival of patients with NSCLC was improved from period D to period E, regardless of the presence of driver gene alteration. We found that next-generation TKIs and ICIs may be associated with improvements in overall survival.http://www.sciencedirect.com/science/article/pii/S2666364323000632Non–small cell lung cancerLong-term survival dataReal-worldA tyrosine kinase inhibitorImmune checkpoint inhibitor |
| spellingShingle | Ryo Ariyasu, MD Sho Kakuto, MD Keiki Miyadera, MD Takahiro Akita, MD Ayu Kiritani, MD Ryosuke Tsugitomi, MD Yoshiaki Amino, MD Ken Uchibori, MD, PhD Satoru Kitazono, MD, PhD Noriko Yanagitani, MD, PhD Makoto Nishio, MD, PhD Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors JTO Clinical and Research Reports Non–small cell lung cancer Long-term survival data Real-world A tyrosine kinase inhibitor Immune checkpoint inhibitor |
| title | Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors |
| title_full | Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors |
| title_fullStr | Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors |
| title_full_unstemmed | Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors |
| title_short | Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors |
| title_sort | real world outcome analysis of patients with stage iv nsclc treated with tyrosine kinase and immune checkpoint inhibitors |
| topic | Non–small cell lung cancer Long-term survival data Real-world A tyrosine kinase inhibitor Immune checkpoint inhibitor |
| url | http://www.sciencedirect.com/science/article/pii/S2666364323000632 |
| work_keys_str_mv | AT ryoariyasumd realworldoutcomeanalysisofpatientswithstageivnsclctreatedwithtyrosinekinaseandimmunecheckpointinhibitors AT shokakutomd realworldoutcomeanalysisofpatientswithstageivnsclctreatedwithtyrosinekinaseandimmunecheckpointinhibitors AT keikimiyaderamd realworldoutcomeanalysisofpatientswithstageivnsclctreatedwithtyrosinekinaseandimmunecheckpointinhibitors AT takahiroakitamd realworldoutcomeanalysisofpatientswithstageivnsclctreatedwithtyrosinekinaseandimmunecheckpointinhibitors AT ayukiritanimd realworldoutcomeanalysisofpatientswithstageivnsclctreatedwithtyrosinekinaseandimmunecheckpointinhibitors AT ryosuketsugitomimd realworldoutcomeanalysisofpatientswithstageivnsclctreatedwithtyrosinekinaseandimmunecheckpointinhibitors AT yoshiakiaminomd realworldoutcomeanalysisofpatientswithstageivnsclctreatedwithtyrosinekinaseandimmunecheckpointinhibitors AT kenuchiborimdphd realworldoutcomeanalysisofpatientswithstageivnsclctreatedwithtyrosinekinaseandimmunecheckpointinhibitors AT satorukitazonomdphd realworldoutcomeanalysisofpatientswithstageivnsclctreatedwithtyrosinekinaseandimmunecheckpointinhibitors AT norikoyanagitanimdphd realworldoutcomeanalysisofpatientswithstageivnsclctreatedwithtyrosinekinaseandimmunecheckpointinhibitors AT makotonishiomdphd realworldoutcomeanalysisofpatientswithstageivnsclctreatedwithtyrosinekinaseandimmunecheckpointinhibitors |